Summary
Merck & Co., Inc. reported solid financial results for the third quarter and the first nine months of 2020. The company demonstrated revenue growth driven by strong performance in its oncology franchise, particularly Keytruda, and increased alliance revenues from key collaborations. Despite headwinds from the COVID-19 pandemic, which impacted sales of physician-administered products and vaccines, Merck managed to grow its top line through strategic partnerships and continued demand for its established products. Profitability saw a significant increase, boosted by lower operating expenses, including reduced promotional and selling costs, and a decrease in cost of sales, partly due to lower intangible asset impairment charges compared to the prior year. The company continued to invest in its robust research and development pipeline, announcing several strategic acquisitions and collaborations aimed at expanding its oncology and infectious disease portfolios. Merck also provided an update on its planned spin-off of Organon & Co., expected in the second quarter of 2021, which will streamline its business focus.
Financial Highlights
53 data points| Revenue | $10.93B |
| Cost of Revenue | $3.01B |
| Gross Profit | $7.92B |
| R&D Expenses | $3.35B |
| SG&A Expenses | $2.06B |
| Operating Income | $7.14B |
| Interest Expense | $203.00M |
| Net Income | $2.94B |
| EPS (Basic) | $1.16 |
| EPS (Diluted) | $1.16 |
| Shares Outstanding (Basic) | 2.53B |
| Shares Outstanding (Diluted) | 2.54B |
Key Highlights
- 1Merck reported consolidated sales of $12.55 billion for Q3 2020, a 1% increase year-over-year, and $35.48 billion for the first nine months, a 1% increase.
- 2Keytruda sales demonstrated robust growth, increasing by 21% to $3.72 billion in Q3 and by 30% to $10.39 billion year-to-date, driven by new indications and global launches.
- 3Alliance revenues from Lynparza and Lenvima collaborations also showed strong growth, increasing by 59% and 30% respectively in Q3.
- 4The company experienced a significant increase in net income, with Q3 net income attributable to Merck & Co., Inc. rising to $2.94 billion from $1.90 billion in the prior year.
- 5Research and development expenses increased by 6% in Q3 to $3.39 billion, reflecting higher collaboration payments and clinical development spending, partly offset by lower COVID-19 related impacts.
- 6Merck continues to actively pursue strategic business development, including the announced acquisition of VelosBio for $2.75 billion and collaborations with Seagen.
- 7The COVID-19 pandemic negatively impacted Pharmaceutical sales by an estimated $475 million in Q3 and $2.0 billion year-to-date, primarily affecting physician-administered products and vaccines.